Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

Drug discovery has long been criticized for its slow, costly, and failure-prone nature. Traditional approaches, particularly ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

In April 2025, the US Food and Drug Administration (FDA) published a roadmap for leveraging new approach methodologies (NAMs), including in silico approaches such as artificial intelligence (AI), to ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting ...

Learn how AI and machine learning enhance antibody discovery – from structure prediction to binding optimization – with ...

The FDA has placed the credibility of AI's 'context of use' in pharma development at the heart of its first guidance in this area.

$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in ...

Discover how Agilent's AssayMAP Bravo and RapidFire systems accelerate drug discovery with automation and rapid, reliable ...

The way we study new medicines and treatments is changing quickly. One of the biggest reasons for this change is the use of ...

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...

Overview of Nanotechnology Drug Delivery MarketThe global Nanotechnology Drug Delivery Market is valued at USD 97.98 Billion ...